Up­dat­ed: No­var­tis ax­es PhI­II peanut al­ler­gy tri­al, ex­pects to test 'op­ti­mized dos­ing' in new tri­al lat­er this year

No­var­tis has again culled a late-stage tri­al of a bi­o­log­ic that it once thought could suc­ceed Xo­lair, its Genen­tech-part­nered an­ti-in­flam­ma­to­ry treat­ment for asth­ma and oth­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER